Health Canada has approved the enVista® Envy™ full visual range intraocular lens (IOL), according to the manufacturer, Bausch + Lomb. The IOL has not yet been approved by the U.S. Food and Drug Administration.
The approval was based on results from a multicenter, randomized, controlled trial that assessed the enVista Envy IOL in Canadian patients. The study found that 93% of patients reported little to no bothersome dysphotopsia, and 94% reported little to no difficulty viewing close objects.
“Today’s cataract patients live vibrant, active lives and have high expectations for vision following surgery,” said Adam Muzychuk, MD, of the University of Calgary, in a press release. “The attributes of enVista Envy, particularly its full range of vision, with very low rates of visual disturbances, position it as an exciting option for patients hoping to live life with greater freedom from glasses and contact lenses. I look forward to offering it in my practice.”
Bausch + Lomb is also seeking regulatory approval for the lens in the United States and Europe.
Reference
Bausch + Lomb receives Health Canada approval for enVista® Envy™* full visual range intraocular lens. Bausch + Lomb press release. May 28, 2024. Accessed May 28, 2024. https://www.bausch.com/news/?id=212
Related Content
